### INTRODUCTION

- **Neuropathic Pain** is commonly described by patients as burning or electrical in nature and results from injury or damage to the nervous system (Hemdon et al 2017). Management of neuropathic pain may prove challenging due to unpredictable patient response to drug therapy (Attal et al 2010).
- **Fibromyalgia** is characterized by chronic musculoskeletal pain with unknown etiology and pathophysiology. Patients typically complain of widespread musculoskeletal pain, fatigue, cognitive disturbance, psychiatric symptoms, and multiple somatic symptoms (Goldenberg 2016[a]). Fibromyalgia is often difficult to treat and requires a multidisciplinary, individualized treatment program (Goldenberg 2016[b]).
- This review focuses on medications that are approved by the Food and Drug Administration (FDA) for the treatment of fibromyalgia, neuropathic pain, and/or post-herpetic neuralgia (PHN). The products in this review include Cymbalta (duloxetine), Gralise (gabapentin ER), Horizant (gabapentin enacarbil ER), Lidoderm (lidocaine 5% patch), Lyrica (pregabalin), Lyrica CR (pregabalin ER), Neurontin (gabapentin), Nucynta ER (tapentadol ER), Qutenza (capsaicin), and Savella (milnacipran). These agents represent a variety of pharmacologic classes, including anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), extended-release (ER) opioids, and topical analgesics. As such, these agents hold additional FDA-approved indications that are outlined in Table 2; however, clinical information included within this review will not address the use of these agents for these additional indications (Prescribing information: Cymbalta 2017, Gralise 2015, Horizant 2016, Lidoderm 2015, Lyrica 2017, Lyrica CR 2017, Neurontin 2017, Nucynta ER 2017, Qutenza 2013, Savella 2017).
  - In February 2018, the FDA approved ZTlido (lidocaine 1.8% topical system) for the relief of pain associated with PHN. The product is not yet available commercially.
  - One ZTlido 1.8% topical system provides equivalent lidocaine exposure to one Lidoderm 5% patch.

### Diabetic Neuropathy

- Approximately 50% of patients with diabetes will eventually develop neuropathy. The high rate of diabetic neuropathy results in substantial patient morbidity, which includes recurrent lower extremity infections, ulcerations, and subsequent amputations (Feldman et al 2015[a]).
  - The condition is categorized into distinct syndromes based on the neurologic distribution, although syndromes may overlap in some patients. The most frequently encountered diabetic neuropathies include distal symmetric polyneuropathy, autonomic neuropathy, polyradiculopathies, and mononeuropathies (Feldman et al 2015[a]).
  - The 3 main components to the management of diabetic neuropathy are glycemic control, foot care, and pain management (Feldman et al 2017[b]).
    - Optimal glucose control is important for the prevention of diabetic neuropathy. Clinical trial evidence demonstrates that rigorous blood glucose control in patients with type 1 diabetes reduces the occurrence of diabetic neuropathy. In contrast, the role of glycemic control in established diabetic neuropathy is uncertain. Limited evidence suggests that neuropathic symptoms may improve with intensive antidiabetic therapy (Feldman et al 2017[b]).
    - Patients with diabetes should be counseled on the importance of daily foot care, including the inspection of feet for the presence of dry or cracking skin, fissures, and plantar callus formation. Regular foot examinations by a healthcare provider are also important (Feldman et al 2017[b]).
    - A small proportion of patients with diabetic neuropathy will experience painful symptoms, and in some instances the condition is self-limited. When treatment is necessary, options include antidepressants, anticonvulsants, capsaicin cream, lidocaine patches, alpha-lipoic acid, isosorbide dinitrate topical spray, and transcutaneous electrical nerve stimulation (Feldman et al 2017[b]).
Fibromyalgia

- Fibromyalgia is a chronic functional illness marked by widespread musculoskeletal pain for which no alternative cause can be identified. Fibromyalgia patients often experience neuropsychological symptoms of fatigue, unrefreshing sleep, cognitive dysfunction, anxiety, and depression (Clauw et al 2009).
  - Patients with fibromyalgia have pain that is typically above and below the waist on both sides of the body and involves the axial skeleton (neck, back, or chest). The pain attributable to fibromyalgia is poorly localized, difficult to ignore, severe in its intensity, and associated with a reduced functional capacity (Crofford 2015).
- The prevalence of fibromyalgia in the general US population is estimated to be 2% (Williams et al 2009). It is more common in women than in men, with a ratio of approximately 9:1 (Crofford 2015).
- There is an increased prevalence of other syndromes associated with pain and fatigue, including chronic fatigue syndrome, temporomandibular disorder, chronic headaches, irritable bowel syndrome, interstitial cystitis/painful bladder syndrome, and other pelvic pain syndromes in fibromyalgia patients (Clauw et al 2009, Crofford 2015).

PHN

- PHN is generally defined as the persistence of the pain of herpes zoster for more than three months after resolution of the rash. It affects 10 to 15% of patients with herpes zoster, with incidence increasing with age. The duration of PHN is highly variable among individuals (Dubinsky et al 2004).
- PHN, as well as acute herpetic neuralgia, can be a severe condition associated with profound psychological dysfunction, including impaired sleep, decreased appetite, and decreased libido (Bajwa et al 2017).
- Prevention of PHN involves either treatment of acute herpes zoster infection or use of a vaccine (Bajwa et al 2017). Administration of antiviral agents within 72 hours of the onset of herpes zoster can reduce the intensity and duration of acute illness, and can also prevent PHN. This may also be achieved with the administration of the tricyclic antidepressant, amitriptyline (Dubinsky et al 2004).
- A number of treatment modalities have been evaluated in the management of PHN and include tricyclic antidepressants, anticonvulsants, opioids, capsaicin, topical lidocaine, intrathecal glucocorticoids, N-methyl-D-aspartate receptor antagonists, botulinum toxin, cryotherapy, and surgery (Bajwa et al 2017).

Table 1. Medications Included Within Class Review

<table>
<thead>
<tr>
<th>Drug</th>
<th>Generic Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cymbalta (duloxetine delayed-release)</td>
<td>✓</td>
</tr>
<tr>
<td>Gralise (gabapentin ER)*</td>
<td>-</td>
</tr>
<tr>
<td>Horizant (gabapentin enacarbil ER)*</td>
<td>-</td>
</tr>
<tr>
<td>Lidoderm (lidocaine transdermal patch)</td>
<td>✓</td>
</tr>
<tr>
<td>Lyrica (pregabalin)</td>
<td>-</td>
</tr>
<tr>
<td>Lyrica CR (pregabalin ER)</td>
<td>-</td>
</tr>
<tr>
<td>Neurontin (gabapentin)*</td>
<td>✓</td>
</tr>
<tr>
<td>Nucynta ER (tapentadol ER)</td>
<td>-</td>
</tr>
<tr>
<td>Qutenza (capsaicin transdermal patch)</td>
<td>-</td>
</tr>
<tr>
<td>Savella (milnacipran)</td>
<td>-</td>
</tr>
<tr>
<td>ZTlido (lidocaine topical system)</td>
<td>-</td>
</tr>
</tbody>
</table>

* Medication is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.

† ZTlido is not yet available commercially.

(Drugs@FDA 2018, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2018)
## INDICATIONS

### Table 2. FDA-Approved Indications

<table>
<thead>
<tr>
<th>Indication</th>
<th>Cymbalta (duloxetine)</th>
<th>Gralise (gabapentin ER)</th>
<th>Horizant (gabapentin enacarbil ER)</th>
<th>Lidoderm (lidocaine)</th>
<th>Lyrica (pregabalin)</th>
<th>Lyrica CR (pregabalin ER)</th>
<th>Neurontin (gabapentin)</th>
<th>Nucynta ER (tapentadol)</th>
<th>Qutenza (capsaicin)</th>
<th>Savella (milnacipran)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjunctive therapy for adult patients with partial onset seizures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients &gt; 3 years of age with epilepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjunctive therapy for patients 4 years of age and older with partial onset seizures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of chronic musculoskeletal pain</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of fibromyalgia</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of neuropathic pain associated with diabetic peripheral neuropathy</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of neuropathic pain associated with spinal cord injury</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of PHN</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relief of pain associated with PHN</td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate-to-severe primary restless legs syndrome</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of generalized anxiety disorder</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of major depressive disorder</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of moderate to severe chronic pain in adults</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓✓</td>
<td>§</td>
</tr>
</tbody>
</table>

† This has been established in studies of patients with chronic low back pain and chronic pain due to osteoarthritis.
‡ Gabapentin enacarbil is not indicated for patients who are required to sleep during the day and remain awake at night.
§ Indicated when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Medication is not for use as: an as-needed analgesic; for pain that is mild or not expected to persist for an extended period of time; for acute pain; or for postoperative pain, unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time.


- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.
Neuropathic Pain


- Tapentadol ER demonstrated superiority over placebo in alleviating pain and improving quality of life in patients with diabetic peripheral neuropathy. Tapentadol ER is associated with significant improvements in pain intensity scores, responder rates, and patient global impression of change (FGIC). Commonly reported AEs in patients receiving tapentadol ER include nausea, vomiting, and constipation (Schwartz et al. 2011).

- Duloxetine demonstrated consistent superiority over placebo in alleviating pain, improving functional outcomes, and improving quality of life in patients with diabetic peripheral neuropathic pain. Specifically, duloxetine is associated with significant improvements in Brief Pain Inventory, Clinician and Patient Global Impression of Improvement and Severity, Short Form-36 Health Survey (SF-36), Pain-Related Sleep Interference, and Euro Quality of Life assessment (EQ-5D) scores. Commonly reported AEs in patients receiving duloxetine include nausea, somnolence, anorexia, and dysuria (Armstrong et al. 2007, Kajdasz et al. 2007, Lunn et al. 2014, Parsons et al. 2016, Yan et al. 2010).

- Head-to-head trials among the neuropathic pain and fibromyalgia agents are rare. In a 52-week, open-label trial comparing duloxetine to routine care (gabapentin, amitriptyline, and venlafaxine) for the treatment of diabetic peripheral neuropathic pain, there were no significant differences observed between groups in EQ-5D questionnaire scores; however, results differed with regards to SF-36 subscale scores. In another trial, there were no significant between-group differences in SF-36 subscale scores; however, other subscale scores for physical functioning, bodily pain, mental health, and vitality favored duloxetine (Raskin et al. 2006, Wernicke et al. 2007[b]). A second head-to-head trial demonstrated duloxetine to be noninferior to pregabalin for the treatment of pain in patients with diabetic peripheral neuropathy who had an inadequate pain response to gabapentin (Tanenberg et al. 2011). A post-hoc analysis of study patients who were taking concomitant antidepressants and those who were not taking antidepressants found duloxetine may provide better pain reduction in those patients who were not taking concomitant antidepressants (Tanenberg et al. 2014). Another head-to-head trial found high-dose duloxetine or pregabalin monotherapy had no significant differences, as measured by Brief Pain Inventory Modified Short Form (BPI-MSF) average pain in comparison, with combination duloxetine and pregabalin therapy (Tesfaye et al. 2013).

- Several large meta-analyses and systematic reviews have been conducted evaluating the neuropathic pain and fibromyalgia agents, which further support the safety and efficacy of these agents in FDA-approved indications (Chou et al. 2009, Edelsberg et al. 2011, Lunn et al. 2009, Lunn et al. 2014, Meng et al. 2014, Moore et al. 2009, Moore et al. 2014, Quilici et al. 2009, Wernicke et al. 2007[a]). In a meta-analysis by Quilici et al, limited available clinical trial data suitable for indirect comparison demonstrated that duloxetine provides comparable efficacy and tolerability to that of gabapentin and pregabalin for the treatment of diabetic peripheral neuropathic pain (Quilici et al. 2009).

- The efficacy of pregabalin in patients with neuropathic pain associated with spinal cord injury was established in 2 placebo-controlled trials, 1 of 12 weeks duration and the other of 16 weeks duration. Patients had neuropathic pain associated with spinal cord injury for at least 3 months or with relapses and remissions for at least 6 months. Patients were allowed to take opioids, non-opioid analgesics, antiepileptic drugs, muscle relaxants, and antidepressant drugs if doses were stable for 30 days prior to screening. Patients were also allowed to take acetaminophen and nonsteroidal anti-inflammatory drugs during the trial. In both trials, pregabalin (150 to 600 mg/day) significantly improved weekly pain scores, and increased the proportion of patients with at least a 30 or 50% reduction from baseline in pain score compared to placebo (Lyrica prescribing information 2016, Siddall et al. 2006, Vranken et al. 2008).

Fibromyalgia

  - A 2009 meta-analysis on the treatment of fibromyalgia syndrome with antidepressants found that antidepressants were associated with improved health-related quality of life. The largest effect size for pain reduction was seen with
the tricyclic antidepressant, amitriptyline, followed by monoamine oxidase inhibitors, moclobemide and pirlindole (medium effect size). Small effect sizes were observed with the selective serotonin reuptake inhibitors (SSRIs), fluoxetine and paroxetine, and the SNRIs, duloxetine and milnacipran. The authors concluded that short-term treatment with amitriptyline and duloxetine could be considered for fibromyalgia-associated pain and sleep disturbances (Hauser et al 2009[a]).

○ In a meta-analysis of 5 RCTs, gabapentin and pregabalin reduced pain and improved sleep in patients with fibromyalgia. The pooled number-needed-to-treat to achieve ≥ 30% reduction in pain was 8.5. Anxity, depressed mood, and fatigue were not improved with gabapentin or pregabalin treatment (Hauser et al 2009[b]).

○ Results from another 2010 meta-analysis noted that duloxetine, milnacipran, and pregabalin have short-term (up to 6-month) efficacy data. The authors concluded that the choice of medication may be dependent on the differences with regard to the occurrence of the key symptoms of fibromyalgia syndrome and to AEs specific to individual drug (Hauser et al 2010).

○ A systematic review and meta-analysis of 10 randomized trials involving 6038 patients concluded that duloxetine and milnacipran provided a small incremental benefit over placebo in pain reduction, and that the dropout rates for duloxetine and milnacipran due to AEs were higher than placebo (Hauser et al 2013).

○ A systematic review of 6 randomized trials involving 2249 patients concluded that for the treatment of fibromyalgia, duloxetine 60 and 120 mg/day are effective with a similar magnitude of effect (low quality evidence). The effect in fibromyalgia may be achieved through a greater improvement in mental symptoms than somatic physical pain (Lunn et al 2014).

○ A 2016 network meta-analysis of 9 RCTs (N = 5140) indirectly compared duloxetine, pregabalin, and milnacipran in the treatment of fibromyalgia. The probability of achieving > 30% improvement in pain scores was numerically highest with duloxetine 60 mg, followed by pregabalin 300 mg, milnacipran 100 mg, and milnacipran 200 mg. While the aforementioned treatment groups each demonstrated superiority over placebo, differences between active treatments did not achieve statistical significance (Lee and Song 2016).

**PHN**

- In patients with PHN, treatment with lidocaine 5% resulted in significant pain relief compared to placebo (Galer et al 1999, Galer et al 2002, Meier et al 2003). In addition, treatment with lidocaine 5% was associated with higher rates of patient preference, less use of rescue medication, and decreases in allodynia and neuropathic symptoms compared to placebo (Galer et al 1999, Meier et al 2003). An open-label trial evaluating lidocaine 5% for the management of PHN supports the findings of placebo-controlled trials (Katz et al 2002).

  - Lidocaine 1.8% was approved via the 505(b)(2) pathway with no new efficacy trials. However, in a single-dose, crossover study conducted in 53 healthy volunteers, lidocaine 1.8% topical system demonstrated equivalent exposure (AUC) and peak concentration (Cmax) of lidocaine to lidocaine 5% patch. In addition, based on a clinical study in 54 subjects, 47 subjects (87%) had adhesion scores of 0 (≥ 90% adhered) for all evaluations performed every 3 hours during the 12 hours of lidocaine 1.8% administration, 7 subjects (13%) had adhesion scores of 1 (≥ 75% to < 90% adhered) for at least 1 evaluation, and no subjects had scores of 2 or greater (< 75% adhered) (ZTtido prescribing information 2018).

- In patients with PHN, treatment with capsaicin resulted in significant pain relief compared to low dose capsaicin 0.04% (Backonja et al 2008, Derry et al 2017, Irving et al 2012). Treatment with capsaicin was associated with improvement in PGIC, reduction in numeric pain rating scale (NPRS) scores, and reduction in neuropathic symptoms compared to low-dose capsaicin for up to 12 weeks of treatment (Backonja et al 2008, Derry et al 2017, Irving et al 2012). The long-term tolerability and safety of capsaicin was also demonstrated in a 52-week study, which found that repeat treatment with capsaicin (30 and 60 minutes) in addition to the standard of care therapies (antidepressants, antiepileptics, and/or opioids) was well tolerated with no negative functional or neurological effects when compared to standard of care therapies alone (Vinik et al 2016).

- Gabapentin also demonstrated superiority over placebo in alleviating pain, improving functional outcomes, and improving quality of life in patients with PHN. Treatment with gabapentin significantly improved average daily pain and sleep, Short form-McGill Pain Questionnaire (SF-MPQ), Patient and Clinician Global Impression of Change, SF-36, and Prolif of Mood States (POMS) scores in RCTs. Commonly reported AEs in patients receiving gabapentin included somnolence, drowsiness, dizziness, ataxia, peripheral edema, and infection (Rice et al 2001, Rowbotham et al 1998). In a trial comparing placebo, gabapentin monotherapy, morphine sustained-release monotherapy, and gabapentin and morphine sustained-release combination therapy, combination therapy achieved better analgesia at lower doses of each.
agent compared to monotherapy with either agent in patients with PHN. Combination therapy was most commonly associated with constipation, sedation, and dry mouth (Gilron et al 2005). Within these clinical trials, doses of gabapentin of up to 3,600 mg/day were evaluated (Gilron et al 2005, Rice et al 2001, Rowbotham et al 1998).

In 2 placebo-controlled trials, gabapentin ER achieved significant improvements in average daily pain and sleep interference scores (Irving et al 2009, Wallace et al 2010). In one of these trials, a larger proportion of patients receiving gabapentin ER reported ≥ 50% reduction from baseline in average daily pain scores compared to placebo (Irving et al 2009). In general, treatment with gabapentin ER was well tolerated; dizziness, headache, somnolence, and peripheral edema were the most commonly reported AEs (Irving et al 2009, Wallace et al 2010). Another placebo-controlled trial concluded that gabapentin ER may be particularly effective in patients with PHN presenting with sharp, dull, sensitive, or itchy pain (Jensen et al 2009). Within these clinical trials, doses of gabapentin ER of up to 1,800 mg/day were evaluated (Irving et al 2009, Jensen et al 2009, Wallace et al 2010).

The efficacy of gabapentin enacarbil ER (1200, 2400, and 3600 mg/day) was established in a randomized, placebo-controlled, 12-week trial in adult patients with a documented medical diagnosis of PHN for ≥ 3 months (N = 371) and significant pain, as demonstrated by a minimum baseline 24-hour average Pain Intensity Numerical Rating Scale score ≥ 4 on the 11-point scale. Treatment with gabapentin enacarbil ER significantly improved the mean pain score and increased the proportion of patients with ≥ 50% reduction in pain score from baseline at all doses evaluated. A benefit over placebo was observed for all 3 doses of gabapentin enacarbil ER as early as Week 1 and was maintained at Week 12. Additional benefit of using doses of gabapentin enacarbil ER > 1200 mg/day was not demonstrated (Zhang et al 2013). Results of a second, published, placebo-controlled trial confirms these findings. Reported AEs were similar to those of gabapentin and gabapentin ER (ie, dizziness, headache, and nausea) (Backonja et al 2011).

A meta-analysis of 7 trials evaluating gabapentin, gabapentin enacarbil ER, and gabapentin ER was conducted to determine the efficacy and safety of all gabapentin formulations for management of PHN. Although gabapentin was found to be superior to placebo in terms of pain reduction, global impression of change, and sleep quality, patients taking gabapentin were significantly more likely to experience AEs such as dizziness, somnolence, peripheral edema, ataxia, and diarrhea (Meng et al 2014).

Pregabalin demonstrated consistent superiority over placebo in alleviating diabetic peripheral neuropathic pain and PHN-related pain. Two noncomparative, open-label trials evaluating pregabalin for the management of PHN supports the findings of placebo-controlled trials (Ogawa et al 2010, Xochical-Morales et al 2010). In one of these noncomparative trials, long-term treatment of PHN with pregabalin (52 weeks) was found to be safe and effective (Ogawa et al 2010). Patients with PHN who were transitioned to pregabalin from gabapentin demonstrated no significant difference in pain scores, based on a visual analog scale, with pregabalin compared to gabapentin. However, in a subset of patients who required an increase in the dosage of pregabalin to improve the analgesic effect after the transition, significant improvement in pain scores was observed (Ifuku et al 2011).

Support for efficacy of pregabalin ER in PHN and diabetic peripheral neuropathy was based on the efficacy of Lyrica in these indications and 1 clinical trial in PHN (Lyrica CR prescribing information 2017). In this trial, pregabalin ER demonstrated a significantly longer time to loss of therapeutic response compared with placebo over a 13-week randomized withdrawal phase in a phase 3, double-blind, randomized trial (Huffman et al 2017).

**CLINICAL GUIDELINES**

**Diabetic Neuropathy**

- The 2011 American Academy of Neurology (AAN) guidelines, which were reaffirmed in 2016, recommend the following:
  - If clinically appropriate, pregabalin should be offered for treatment. Gabapentin and sodium valproate are other anticonvulsants that should be considered for treatment (Bril et al 2011).
  - Amitriptyline, venlafaxine, and duloxetine should be considered for treatment; there is insufficient evidence available to recommend one of these agents over another. Combination therapy with venlafaxine and gabapentin may be utilized for a better response.
  - The opioids, dextromethorphan, morphine sulfate, tramadol, and oxycodone should be considered for treatment; there is insufficient evidence available to recommend one of these agents over another.
  - With regards to other pharmacologic options, capsaicin and isosorbide dinitrate spray should be considered for treatment, while lidocaine patch may be considered.
- The 2018 American Diabetes Association (ADA) guideline acknowledges the lack of quality of life outcomes and recommends that treatment decisions follow a trial-and-error approach (ADA 2018).
- Pregabalin, duloxetine, and tapentadol ER have been approved for relief of diabetic peripheral neuropathy; however, none of these agents affords complete relief, even when used in combination.
- Either pregabalin or duloxetine is recommended as initial pharmacologic therapy for neuropathic pain in diabetes. The use of tapentadol ER is generally not recommended as a first or second-line therapy due to safety concerns such as high-risk for addiction, and the evidence for its use is considered weaker.
- Venlafaxine, amitriptyline, gabapentin, carbamazepine, tramadol, and topical capsaicin may also be effective and could be considered for treatment of painful diabetic peripheral neuropathy.

In general, other published guidelines support recommendations from the AAN and ADA concerning the use of the neuropathic pain and fibromyalgia agents in the management of diabetic neuropathy (Dworkin et al 2007, Handelsman et al 2015, Pop-Busui et al 2017).

PHN
- According to the 2004 AAN guidelines, first-line therapies for the management of PHN include tricyclic antidepressants, gabapentin, pregabalin, opioids, and topical lidocaine. The use of these therapies for long-term management remains uncertain (Dubinsky et al 2004).
- In general, other published guidelines support recommendations from the AAN for the use of the neuropathic pain and fibromyalgia agents in the management of PHN (Attal et al 2010, Dworkin et al 2007).

Fibromyalgia
- According to the evidence-based recommendations for the management of fibromyalgia syndrome from the European League Against Rheumatism, non-pharmacologic interventions should be considered first-line therapy for the management of fibromyalgia symptoms. Pharmacologic therapy should only be initiated if there is a lack of effect with non-pharmacologic therapies, and should be tailored to meet the patient’s needs. Recommended pharmacologic agents include low-dose amitriptyline, cyclobenzaprine, duloxetine, milnacipran, pregabalin, and tramadol (Macfarlane 2017).
- According to the 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome, all classes of antidepressants are options for treatment of pain and other symptoms of fibromyalgia. Anticonvulsants are also options, though the guideline does not recommend specific agents (FitzCharles et al 2013).

SAFETY SUMMARY
- Duloxetine and milnacipran carry a boxed warning for clinical worsening, suicidality, and unusual changes in behavior. There is an increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. All SNRIs are not approved for use in pediatric populations. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely, especially during the initial few months of a course of drug therapy and following changes in dosage.
- Tapentadol ER has a boxed warning for the potential for abuse, life-threatening respiratory depression, accidental exposure, risk of neonatal opioid withdrawal syndrome with prolonged use, and interactions with alcohol, benzodiazepines, or other central nervous system depressants that can cause profound sedation, respiratory depression, coma, and death.
- Gabapentin, pregabalin, and pregabalin ER carry warnings regarding the risk of anaphylaxis and/or angioedema after the first dose or during therapy.
- Topical lidocaine products have a warning for excessive dosing/overexposure, increased absorption on non-intact skin, risk of overexposure with external heat sources, and hypersensitivity reactions.
- The following key contraindications are included in the prescribing information:
  - Concomitant use or use within the last 14 days of monoamine oxidase inhibitors is contraindicated with duloxetine, milnacipran, and tapentadol ER.
  - Tapentadol ER is contraindicated in significant respiratory depression, acute or severe bronchial asthmas, or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment, and in known or suspected paralytic ileus.
- The FDA requires a Risk Evaluation and Mitigation Strategy (REMS) program for ER and long-acting opioid analgesics, including tapentadol ER, to assure safe use of these medications.
- The following monitoring parameters are recommended with treatment:
  - Monitor for clinical worsening of depression, suicidality, or unusual changes in behavior with duloxetine, milnacipran, gabapentin ER, gabapentin enacarbil ER, pregabalin, pregabalin ER, and gabapentin treatment.
○ Patients receiving tapentadol ER, duloxetine, or milnacipran should be monitored for signs of serotonin syndrome when used concurrently with other serotonergic agents (eg, SSRIs, SNRIs, tricyclic antidepressants, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort). Tapentadol ER, duloxetine or milnacipran should not be used with drugs that impair metabolism of serotonin (eg, monoamine oxidase inhibitors [MAOIs], linezolid, and methylene blue).
○ Monitor for signs of misuse, abuse, and addiction during tapentadol ER therapy. Patients should also be closely monitored for 72 hours after initiating tapentadol ER treatment and monitored throughout treatment due to an increased risk of respiratory depression.
○ Patients receiving tapentadol ER, duloxetine, capsaicin, or milnacipran should have their blood pressure monitored prior to initiating treatment and periodically throughout treatment.
○ Monitor for worsened seizure control in patients with a history of seizure disorder with the treatment of tapentadol ER, duloxetine, or milnacipran.
○ Patients receiving tapentadol ER should be monitored for signs and symptoms of worsening biliary tract disease, including acute pancreatitis.

- In general, oral neuropathic pain and fibromyalgia agents are commonly associated with central nervous system-related AEs (eg, dizziness, drowsiness, somnolence). Peripheral edema and weight gain may also occur with use of these agents.

### DOSING AND ADMINISTRATION

<table>
<thead>
<tr>
<th>Drug</th>
<th>Available Formulations</th>
<th>Route</th>
<th>Usual Recommended Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cymbalta (duloxetine delayed-release)</td>
<td>Capsule</td>
<td>Oral</td>
<td>Once daily</td>
<td>Not recommended in ESRD, severe renal impairment (CrCl &lt; 30 mL/min), or hepatic insufficiency</td>
</tr>
<tr>
<td>Gralise (gabapentin ER)</td>
<td>Tablet</td>
<td>Oral</td>
<td>Once daily</td>
<td>Administer with evening meal Reduce dose in CrCl of 30 to 60 mL/min; not recommended in CrCl &lt; 30 mL/min or hemodialysis</td>
</tr>
<tr>
<td>Horizant (gabapentin enacarbil ER)</td>
<td>Tablet</td>
<td>Oral</td>
<td>Twice daily</td>
<td>Administer with food Reduce dose in CrCl &lt; 60 mL/min or hemodialysis</td>
</tr>
<tr>
<td>Lidoderm, ZTlido (lidocaine)</td>
<td>Patch, topical system</td>
<td>Transdermal</td>
<td>Once daily</td>
<td>Apply for up to 12 hours within a 24-hour period Caution in patients with severe hepatic disease</td>
</tr>
<tr>
<td>Lyrica (pregabalin)</td>
<td>Capsule, oral solution</td>
<td>Oral</td>
<td>2 or 3 times daily</td>
<td>Schedule V controlled substance Reduce dose in CrCl &lt; 60 mL/min</td>
</tr>
<tr>
<td>Lyrica CR (pregabalin ER)</td>
<td>Tablet</td>
<td>Oral</td>
<td>Once daily</td>
<td>Schedule V controlled substance Reduce dose in CrCl &lt; 60 mL/min Administer after evening meal</td>
</tr>
<tr>
<td>Neurontin (gabapentin)</td>
<td>Capsule, oral solution, tablet</td>
<td>Oral</td>
<td>3 times daily</td>
<td>Reduce dose in CrCl &lt; 60 mL/min</td>
</tr>
<tr>
<td>Nucynta ER (tapentadol ER)</td>
<td>Tablet</td>
<td>Oral</td>
<td>Twice daily</td>
<td>Schedule II controlled substance Do not use in severe renal impairment (CrCl &lt; 30 mL/min) or severe hepatic impairment Reduce dose in moderate hepatic impairment</td>
</tr>
<tr>
<td>Quenta (capsaicin)</td>
<td>Patch</td>
<td>Transdermal</td>
<td>60-minute application of up to 4 patches every 3 months</td>
<td>Only administered by physicians or health care professionals</td>
</tr>
</tbody>
</table>

Data as of August 21, 2018 AS/KAL
This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
CONCLUSION

- Included in this review are the neuropathic pain and fibromyalgia agents, duloxetine, gabapentin ER, gabapentin enacarbil ER, lidocaine, pregabalin, pregabalin ER, gabapentin, tapentadol ER, capsaicin, and milnacipran. In general, these agents are FDA-approved for the treatment of diabetic peripheral neuropathic pain, PHN, and/or fibromyalgia.
- Clinical trials support the use of the neuropathic pain and fibromyalgia agents for their FDA-approved indications. Available data demonstrate that neuropathic pain and fibromyalgia agents provide relief from pain; some studies have demonstrated improvement in functional outcomes and quality of life. Direct comparisons among the various agents are rare, and consistent benefit of one agent over another has not been demonstrated.
- According to the available literature, tricyclic antidepressants and duloxetine demonstrate an ability to provide pain relief in patients with painful diabetic neuropathy. While pregabalin and valproate have both demonstrated usefulness in the management of diabetic neuropathy, available literature suggests that the utility of gabapentin is less certain. There is minimal evidence evaluating the use of topical lidocaine for the management of painful diabetic neuropathy. Strong opioids have demonstrated efficacy compared to placebo; however, prescribers may consider this as last line therapy due to concerns regarding long-term safety, including addiction potential and misuse (Attal et al 2010, Feldman et al 2017[b], Schwartz et al 2011).
  - Of the neuropathic pain and fibromyalgia agents included in the review, duloxetine, pregabalin, pregabalin ER, and tapentadol ER are approved for the management of diabetic neuropathy.
- For the management of PHN, available literature demonstrates that tricyclic antidepressants, gabapentin, pregabalin, opioids, topical capsaicin, botulinum toxin, and topical lidocaine are more effective compared to placebo (Bajwa et al 2017).
  - Of the neuropathic pain and fibromyalgia agents included in this review, gabapentin ER, gabapentin enacarbil ER, lidocaine, pregabalin, pregabalin ER, gabapentin, and capsaicin are approved for the management or relief of pain associated with PHN.
- For the management of fibromyalgia, available literature demonstrates that amitriptyline, cyclobenzaprine, duloxetine, gabapentin, milnacipran, and pregabalin are all appropriate treatment options. The choice of therapy is guided by specific symptoms, comorbidities, and patient preference (Goldenberg 2016[b]).
  - Of the neuropathic pain and fibromyalgia agents included in this review, duloxetine and pregabalin are approved for fibromyalgia.

REFERENCES


Data as of August 21, 2018 AS/KAL

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.


This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.


Publication Date: August 22, 2018